Your browser doesn't support javascript.
loading
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz, Luis J; Hutchinson, Katherine E; Rexer, Brent N; Estrada, Mónica Valeria; Gonzalez Ericsson, Paula I; Sanders, Melinda E; Dugger, Teresa C; Formisano, Luigi; Guerrero-Zotano, Angel; Red-Brewer, Monica; Young, Christian D; Lantto, Johan; Pedersen, Mikkel W; Kragh, Michael; Horak, Ivan D; Arteaga, Carlos L.
Affiliation
  • Schwarz LJ; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Hutchinson KE; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Rexer BN; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Estrada MV; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Gonzalez Ericsson PI; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Sanders ME; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Dugger TC; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Formisano L; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Guerrero-Zotano A; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Red-Brewer M; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Young CD; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Lantto J; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Pedersen MW; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Kragh M; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Horak ID; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
  • Arteaga CL; Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Balleru
J Natl Cancer Inst ; 109(11)2017 11 01.
Article in En | MEDLINE | ID: mdl-29059433
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antibodies, Neutralizing / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: J Natl Cancer Inst Year: 2017 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antibodies, Neutralizing / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: J Natl Cancer Inst Year: 2017 Type: Article